Glaukos Co. (NYSE:GKOS) Receives $99.80 Consensus PT from Brokerages

Glaukos Co. (NYSE:GKOS) has earned an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $99.80.

A number of analysts have recently weighed in on the company. Mizuho upped their target price on Glaukos from $85.00 to $100.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Needham & Company LLC upped their price objective on shares of Glaukos from $105.00 to $108.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Truist Financial reaffirmed a “buy” rating and set a $110.00 price target on shares of Glaukos in a report on Monday, April 8th. Wells Fargo & Company upped their price target on shares of Glaukos from $83.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, February 22nd. Finally, StockNews.com cut Glaukos from a “hold” rating to a “sell” rating in a research note on Tuesday, February 27th.

Glaukos Trading Up 2.1 %

Glaukos stock opened at $101.06 on Friday. Glaukos has a 52 week low of $45.38 and a 52 week high of $102.33. The company has a debt-to-equity ratio of 0.77, a quick ratio of 4.78 and a current ratio of 5.34. The stock has a market capitalization of $5.07 billion, a P/E ratio of -36.35 and a beta of 1.08. The stock has a 50-day simple moving average of $91.93 and a 200 day simple moving average of $81.08.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.07). The company had revenue of $82.40 million for the quarter, compared to the consensus estimate of $81.00 million. Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The business’s quarterly revenue was up 15.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.53) EPS. Analysts expect that Glaukos will post -2.18 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Alex R. Thurman sold 434 shares of the company’s stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $95.33, for a total transaction of $41,373.22. Following the completion of the sale, the chief financial officer now owns 54,166 shares in the company, valued at $5,163,644.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CFO Alex R. Thurman sold 434 shares of the stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $95.33, for a total transaction of $41,373.22. Following the completion of the transaction, the chief financial officer now owns 54,166 shares in the company, valued at $5,163,644.78. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Alex R. Thurman sold 1,372 shares of the stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $100.54, for a total transaction of $137,940.88. Following the transaction, the chief financial officer now directly owns 52,532 shares of the company’s stock, valued at $5,281,567.28. The disclosure for this sale can be found here. In the last ninety days, insiders sold 242,357 shares of company stock valued at $22,857,372. Corporate insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in GKOS. Natixis Advisors L.P. raised its position in shares of Glaukos by 4.0% in the third quarter. Natixis Advisors L.P. now owns 33,979 shares of the medical instruments supplier’s stock worth $2,557,000 after buying an additional 1,298 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Glaukos by 5.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 386,790 shares of the medical instruments supplier’s stock valued at $29,106,000 after acquiring an additional 20,415 shares in the last quarter. Wealthcare Advisory Partners LLC bought a new stake in shares of Glaukos during the 3rd quarter valued at about $204,000. Lisanti Capital Growth LLC purchased a new position in shares of Glaukos during the third quarter worth about $6,367,000. Finally, Louisiana State Employees Retirement System bought a new position in shares of Glaukos in the fourth quarter worth approximately $1,940,000. Institutional investors own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.